Trial Profile

Phase III study of Carboplatin/Paclitaxel versus UFT for the patient with completely resected pathological stage IB-IIIA of Non Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Tegafur/uracil (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

02 Mar 2018 Results assessing safety and efficacy published in the Journal of Thoracic Oncology
07 Jun 2016 Primary endpoint (The 5-year overall survival) has not been met according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
07 Jun 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com